Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Lilly | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Lilly

Patent expirations pummel results

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Lilly
 
2Q Revenues: $4.9 billion (-17%)

2Q Earnings: $733.5 million (-39%)

YTD Revenues: $9.6 billion (-17%)

YTD Earnings: $1.5 billion (-47%)

Comments: Results were impacted by the loss of U.S. patent exclusivity for Cymbalta, down 73% in the quarter to $401.3 billion, and Evista, down 61% to $108.3 million. Alimta sales were up 6% to $669.4 million. Humalog sales were up 11% to $628.6 million. Cialis sales were up 7% to $567.8 million. Lilly launched Cyramza in the quarter for gastric cancer or gastroesophageal junction (GEJ).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters